The Great Experiment is almost two years old.
Results still coming in!
The following is a collection of articles over the last week:
From the article:
Florida Surgeon General Dr. Joseph A. Ladapo announced new guidance on messenger RNA (mRNA) vaccines on Oct. 7, specifically recommending against administering mRNA COVID-19 vaccines to males aged 18 to 39.
Messenger RNA is the technology utilized by both the Pfizer and Moderna COVID-19 vaccines, the most administered vaccines in the United States and a number of other countries.
The new guidance follows a Florida Department of Health analysis to evaluate vaccine safety, the department said in a bulletin.
The statewide analysis of vaccinated Florida residents aged 18 years or older (pdf) found an 84 percent increase in the relative incidence of cardiac-related deaths among males aged 18–39, within 28 days of mRNA vaccination.
“Non-mRNA vaccines were not found to have these increased risks,” the Florida Department of Health noted.
Given the high level of global immunity to COVID-19, the benefit of vaccination with mRNA vaccines “is likely outweighed by this abnormally high risk of cardiac-related death among men in this age group,” the department said.
“As such, the State Surgeon General recommends against males aged 18 to 39 from receiving mRNA COVID-19 vaccines,” it said. “Those with preexisting cardiac conditions, such as myocarditis and pericarditis, should take particular caution when making this decision.”
“Far less attention has been paid to safety and the concerns of many individuals have been dismissed—these are important findings that should be communicated to Floridians,” Ladapo said in a statement, referring to the analysis.
In the new guidance (pdf), Florida’s health department said it also “continues to stand by” its guidance for pediatric COVID-19 vaccines it issued in March. That guidance (pdf) recommends against COVID-19 vaccination for healthy children and adolescents aged 5–17. It now also recommends against COVID-19 vaccination among infants and children under five years old.
From the article:
The effectiveness of three doses—a primary series and a booster—against infection remained above 50 percent after 150 days against BA.1, a subvariant of the Omicron virus variant, researchers estimated.
However, against more recent strains, including the currently dominant BA.5, the effectiveness turned negative. Against BA.2, BA.4, and BA.5, the effectiveness went negative after 150 days; against BA.1.12.1, the effectiveness turned negative after 91 days.
Negative effectiveness means that a vaccinated person is more likely to contract COVID-19, the disease caused by the virus, than an unvaccinated person….
From the article:
Member of the European Parliament, Rob Roos, asked during a session: “Was the Pfizer COVID vaccine tested on stopping the transmission of the virus before it entered the market? Did we know about stopping immunization before it entered the market?”
Pfizer’s Janine Small, president of international developed markets, said in response: “No … You know, we had to … really move at the speed of science to know what is taking place in the market.”
Roos, of the Netherlands, argued in a Twitter video Monday that following Small’s comments to him, millions of people around the world were duped by pharmaceutical companies and governments.
“Millions of people worldwide felt forced to get vaccinated because of the myth that ‘you do it for others,’” Roos said. “Now, this turned out to be a cheap lie” and “should be exposed,” he added.
The Epoch Times has contacted Pfizer for comment….
From the article:
The data collected from Israel’s adverse events reporting system showing that some women experienced menstrual disorders for more than 12 months after receiving a COVID-19 vaccine raises concerns, according to Dr. Shelly Cole, an obstetrician-gynecologist in Texas.
“Looking at the Israeli data is very concerning,” Cole told The Epoch Times.
Of the 282 Israeli women who reported menstrual abnormality following COVID-19 vaccination, 88 reports contained information on the duration of the condition. And of the 88 reports, 83 disclosed that the menstrual problems lasted over a week. Some of the women’s problems had still not resolved.
All but one of the reports were from adults. The single child report detailed a disorder lasting between one and six months.
Of the other 82 reports, 11 reported that their condition lasted between one week to one month, 42 that their condition lasted one to six months, 22 that they suffered for six to 12 months, and seven that their condition lasted for over 12 months.
The reports were from women who received a Pfizer or Moderna COVID-19 vaccine. The reports were submitted between December 2021 and May 2022. They were discussed during a secret meeting over the summer.
Health experts say the actual number of menstrual cases is much higher than what is being reported to the system and others like it. Many women may have thought that their condition was not vaccine-related, been unaware of the reporting system, or not been encouraged by their doctor to lodge a report….
Come across this article from last month:
BY KORIN MILLER PUBLISHED: SEP 6, 2022
And they hope to create a new vaccine with it.
COVID-19 vaccines have been effective at keeping people from getting severely ill and dying from the virus, but they’ve required different boosters to try to keep on top of all of the coronavirus variants that have popped up. Now, researchers have discovered an antibody that neutralizes all known COVID-19 variants.
The antibody, called SP1-77, is the result of a collaborative effort from researchers at Boston Children’s Hospital and Duke University. Results from mouse studies they’ve conducted were recently published in the journal Science Immunology, and they look promising.
But what does it mean, exactly, to have an antibody that can neutralize all variants of COVID-19, and what kind of impact will this have on vaccines in the future? Here’s what you need to know.
What is SP1-77?
SP1-77 is an antibody developed by researchers that so far can neutralize all forms of SARS-CoV-2, the virus that causes COVID-19. It was created after researchers modified a mouse model that was originally made to search for broadly neutralizing antibodies to HIV, which also mutates.
The mice used in the study have built-in human immune systems that mimic the way our immune systems develop better antibodies when we’re exposed to a pathogen. The researchers inserted two human gene segments into the mice, which then created a range of antibodies that humans might make. The mice were then exposed to SARS-CoV-2’s spike protein (which is what the virus uses to latch onto your cells) and produced nine different families of antibodies that bound to the spike protein to try to neutralize it.
The antibody works in a slightly different way than many of the antibodies people make to vaccines. To infect you, SARS-CoV-2 has to first attach to ACE2 receptors in your cells. The current COVID-19 vaccines block this binding from happening by attaching to the spike protein’s receptor-binding domain (RBD) at certain spots, a press release from Boston Children’s Hospital explains.
The SP1-77 antibody also binds to the RBD, but doesn’t prevent the virus from binding to ACE2 receptors. What it does do is block the virus from fusing its outer membrane with the membrane of your cells, which is what needs to happen to make you sick.
What does this mean for the future of COVID-19 vaccines and treatments?
It’s not clear right now. It’s important to note that this research was done in mice—not humans—although studies on the antibody are ongoing.
“This is very early-stage proof-of-concept work to illustrate that broadly neutralizing antibodies can be generated using a mouse model,” says Amesh A. Adalja, M.D., infectious disease expert and senior scholar at the Johns Hopkins Center for Health Security. “Such work, if replicated and expanded, could form the basis of new monoclonal antibody products as well as a vaccine.”
Experts say that a vaccine that could take out all variants of COVID-19 would definitely be welcome. “We’d love to have a vaccine that is active against all circulating variants, including those yet to come,” says Thomas Russo, M.D., professor and chief of infectious disease at the University at Buffalo in New York. “It’s the holy grail of vaccines.”
That could potentially mean that you would only need to get a COVID-19 shot or booster once a year or even less frequently, depending on how long protection from the vaccine lasted, Dr. Russo says.
The researchers have applied for a patent for the SP1-77 antibody and mouse model used to create it, and plan to create something that can be used by the general public if all goes well.
Can they keep Big Pharma’s nose pickers out of it?
Interesting number for this antibody!
What is the foundation for monoclonal antibodies?
Natural Immune System!
From a Year Ago
Someone famous was treated early on!
“Initially the monoclonal antibodies weren’t used much and a report in December 2020 stated that only 5 to 20 percent of the monoclonal antibodies shipped were being used.”
But who did most trust?
And his Igors!
From the uttermost part of the earth have we heard songs, even glory to the righteous. But I said, My leanness, my leanness, woe unto me! the treacherous dealers have dealt treacherously; yea, the treacherous dealers have dealt very treacherously.
And boosters still being pushed!